IperionX Maintains Analyst Confidence Amid Regulatory Scrutiny

Analyst Neal Dingmann reaffirms buy rating for IperionX, citing major titanium capacity expansion, DoD funding, and key 2026 milestones, despite legal probes and a divided analyst view.

Despite facing ongoing securities investigations, a regulatory query from the Australian Securities Exchange (ASX), and a share price that remains well below its previous highs, IperionX continues to receive a bullish endorsement from at least one prominent market researcher. Neal Dingmann, an analyst at William Blair, has reaffirmed his "buy" rating for the company, a stance that contrasts sharply with the persistent skepticism found elsewhere in the market.

Operational Milestones Counterbalance Headlines

The foundation for William Blair's constructive outlook lies in IperionX's tangible operational progress. A central pillar is the planned seven-fold expansion of its titanium powder production capacity, targeting approximately 1,400 tonnes annually. The company aims to commission this expansion by mid-2027. A significant portion of the project's funding is backed by government support, including a $47.2 million award from the U.S. Department of Defense.

Further developments are anticipated in the second quarter of 2026, with the feasibility study for the Titan Mineral Sands Project scheduled for completion. Concurrently, the new GenX™ platform is expected to achieve commercial readiness later this year. In a move set to positively impact margins, the company has also secured 290 tonnes of titanium scrap at no cost, which is sufficient to support 18 months of operations.

Corporate governance saw strong shareholder support at the Annual General Meeting on March 19. Approximately 95% of votes were cast in favor of granting stock options to CEO Anastasios Arima and Executive Chair Todd Hannigan. Notably, the exercise prices of A$18 and A$22 are positioned substantially above the share price at the time, meaning the compensation will only yield value if the equity appreciates significantly.

A Divided Analytical Landscape

While the official consensus among analysts covering IperionX is optimistic—with an average price target of $61.50 implying an upside of roughly 119% from current levels—a clear dissenting voice exists. One analyst maintains a "sell" recommendation, citing a price target of A$4.00 that suggests minimal room for advancement.

This division stems from a turbulent period in March. On March 13, 2026, IperionX acknowledged a typographical error in its half-year financial report. In the subsequent two trading sessions, the stock declined by approximately 27%. Following this event, several U.S. law firms, including Holzer & Holzer, initiated investigations into potential violations of securities laws.

The coming months will be critical in determining whether the upcoming feasibility study and the GenX™ platform validation can provide the substantive progress needed to bolster investor confidence and justify the bullish thesis held by some.